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ABSTRACT PAGE
T he treatm ent of schizophrenia is heavily reliant on financial, health, and social care.
Despite the low occurrence of schizophrenia in the population, the total health ca re c o sts of
schizophrenia are similar to m ore prevalent mental disorders. Therefore, reso u rces need to
be directed at finding and implementing the m ost effective and least costly treatm ent
regim es. T he current study exam ined differences in weight, lipid and glucose levels, and
m etabolic irregularities betw een schizophrenic patients receiving first and second
generation antipsychotics. R esults indicated that there w as a higher prevalence of
m etabolic disorder am ong patients treated with seco n d generation antipsychotics (SGAs)
than th o se treated with first generation antipsychotics (FGAs). Patients receiving SGAs
also displayed g reater in creases in weight and systolic blood pressure from first to last
a s s e s s m e n t than th o se being treated with FGAs. S econd generation antipsychotics w ere
not superior on m ea su res of clinical efficacy than first generation antipsychotics. In
combination, th e s e findings su g g e st that the benefits of SGAs m ay not outweigh the side
effects and financial cost of this c la ss of antipsychotics.
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Patterns and Prevalence of Metabolic Syndrome Among Persons Receiving Treatment
with Antipsychotic Medications
Schizophrenia is a chronic, deteriorating brain disorder that involves many brain
and neurochemical abnormalities (Andreasen, 1997; Cahn et al., 2002). Patients with
schizophrenia evidence psychological, social, cognitive, and occupational deficits
(Burton, 2006). Compared to the general population, attention/vigilance, working
memory, verbal and visual learning and memory, reasoning and problem solving,
processing speed, and social cognition are disturbed in schizophrenics (Ikebuchi,
Nakagome, & Takahashi, 1999).
Negative symptoms of schizophrenia are often characterized as “deficient
symptoms” because they reflect deficiencies in normal behavior (Shean, 2004). Negative
symptoms include: disorganized speech, grossly disorganized or catatonic behavior,
affective blunting, poverty of speech (alogia), decreased level of activity (avolition),
decreased pleasure (anhedonia), and poor executive functioning and self care skills
(American Psychiatric Association [APA], 2000; Worrel, Marken, Beckman, & Ruehter,
2000). Positive symptoms represent an excess in normal behaviors (Toomey, Seidman,
Lyons, Faraone, & Tsuang, 1999). These symptoms include disorganized thinking,
hallucinations, and delusions.
Costs o f Schizophrenia
Approximately 1% of the population is afflicted with schizophrenia (National
Institute of Mental Health [NIMH], 2005). Despite schizophrenia’s low prevalence, its
costs are similar to more widespread mental illnesses such anxiety disorders (Rice, 1999).
In 2002, the economic burden of schizophrenia was approximately $62.7 billion (Wu et
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al., 2005). Included in the overall health care costs of schizophrenia are direct costs (e.g.,
drug and hospitalization costs) and indirect costs (e.g., loss of productivity:
unemployment, loss of income, and premature death from suicide).
The estimated relapse rate of schizophrenia is as high as 3.5% per month
(Csemansky & Schuchart, 2002). A minority o f schizophrenic patients, approximately
25% (Bleuer, 1978), fully recover. The remaining percentage of schizophrenics either
remain in a state of severe psychosis (10%) or experience acute relapses (65%).
Cognitive deficits affecting memory, social skills, and attention can impede a
schizophrenic's ability to live independently (Velligan et al., 1997) and fulfill social roles
(Gerlach, 2002). These deficits combined with a high incidence of relapse lead to long
and/or frequent and expensive hospital stays. The estimated annual cost of
hospitalizations to relapse among individuals with schizophrenia is $2 billion.
Schizophrenic patients occupy 8.8% of all hospital beds, 11.4% o f all nursing
home beds, and 40.3% of all mental health facility beds (Worrel et al., 2000). Individuals
who are discharged may still require ongoing and costly outpatient care. Therefore, the
high economic costs of relapses and re-hospitalizations associated with schizophrenia
contribute to the high overall health care costs of this disorder.
Comorbidity and Cost
Individuals with schizophrenia often suffer from chronic physical illness (Marder
et al., 2004). Many medical problems arise due to poor nutrition and hygiene, tobacco
usage, inadequate treatment, and serious problems associated with side effects of
antipsychotic medications (Goldman, 1999; Marder et al., 2004; NIMH, 2005; Shean,
2004). Carney, Jones, and Woolson (2006) found that schizophrenic patients have more
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comorbid medical conditions than those without the disorder. Furthermore, over 33% of
persons with schizophrenia had three or more comorbid disorders (Carney et al., 2006).
Carney et al. (2006) found that individuals with schizophrenia have more months of
follow up and more non-mental health care visits than those without schizophrenia.
Compared with the general population, individuals with schizophrenia are more likely to
have respiratory illness even after controlling for the effects of smoking (Sokal et al.,
2004). Current medical problems may exacerbate the psychosis and depression associated
with schizophrenia (Dixon, Postrado, Delahanty, Fischer, & Lehman, 1999), thus making
patients more difficult and expensive to treat. The high prevalence of chronic medical
conditions among individuals with schizophrenia also contributes to increased mortality
(Brown, 1997).
Results from the Epidemiologic Catchment Area (ECA) Study indicate that
approximately 47% of individuals with a lifetime diagnosis of schizophrenia or
schizophreniform disorder also meet the diagnostic criteria for substance abuse.
Individuals with schizophrenia are 4.6 times more likely of having a substance abuse
disorder than those without the disorder (Regier et al., 1990). The high prevalence of
substance abuse and medical problems among schizophrenic patients indicates that the
cost o f care for schizophrenia may be much higher than initial estimates may suggest.
These indirect costs of schizophrenia may contribute to the large proportion of national
health care expenditure on schizophrenia worldwide (Beard, Maciver, Clouth, & Riither,
2006).
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Psychopharmacology o f Schizophrenia
Neurodevelopmental deficits contribute to some of the cognitive and attentional
impairments evident in schizophrenics even before the onset of overt psychoses.
Consequently, these impairments may contribute to a schizophrenic's capacity to be
rehabilitated (Kotrla & Weinberger, 1995; Smith, Hull, Romanelli, Fertuck, & Weiss,
1999). Although the course of schizophrenia varies, patient outcomes are largely
determined by medication (Shean, 2004). The American Psychological Association
(1997) has determined that antipsychotics can lead to a reduction in the relapse rate for
individuals with schizophrenia. Therefore, long-term psychopharmacological treatment
may be necessary for improved disease outcomes.
Studies have identified several anatomical abnormalities in the brains of
schizophrenic patients. However, researchers believe that the symptoms of schizophrenia
result from circulatory dysfunction rather than localized brain areas (Wiser et al., 1998).
Some of the biochemical systems that have been implicated in schizophrenia include the
dopaminergic, glutamate, and the GABA systems (Javitt & Laruelle, 2006).
Dopamine Hypothesis
The dopamine hypothesis is one o f the longest lasting and most influential
explanatory models of schizophrenia (Kapur & Mamo, 2003). According to this
hypothesis, schizophrenia arises as a result of an excess of the neurotransmitter dopamine
(DA) in the brain, which is responsible for the positive symptoms characteristic of
schizophrenia. After the introduction of chlorpromazine in 1952 and other first generation
antipsychotics (FGAs) shortly after, researchers discovered that the biological mechanism
underlying schizophrenia involves D2 receptors, one of the two main families of DA
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receptors. This finding was supported by the correlation between the clinical efficacy of
FGAs and D2 receptor affinity (Horacek et al., 2006; Peroutka & Snyder, 1980).
Therefore, researchers have historically believed that D2 receptors are the major site of
action in schizophrenia. According to the dopamine hypothesis, a hyperfunction of DA
transmission in the striatum accounts for the positive symptoms of schizophrenia.
Antipsychotics work by antagonizing the D2 receptors, which reduces DA levels in the
mesolimbic pathway.
First Generation Antipsychotics
Antipsychotics play a central role in the treatment of schizophrenia and other
psychotic disorders. First generation antipsychotics were formulated to antagonize the D2
receptor. Research has shown that FGAs effectively reduced positive psychotic
symptoms. However, FGAs may worsen the negative symptoms of schizophrenia by
antagonizing DA in the mesocortical pathway where DA is underactive (Shean, 2004).
First generation antipsychotics range in their clinical potency from low to high.
Low potency drugs include Thorazine (chlorpromazine), Mellaril (thioridazine), and
Serentil (mesoridazine). Medium potency drugs include Loxatane (loxapine), Moban
(molindone), and Trilafon (perphenazine). High potency drugs include Haldol
(haloperidol), Prolixin (fluphenazine), Navane (thioxanthene), and Stelazine
(trifluoperazine) (Worrel et al., 2000).
Extra-pyramidal side effects. First generation antipsychotics often produce
extrapyramidal symptoms (EPS). Caesy (1998) estimated that up to 90% of patients on
FGAs experience EPS. The nigrostriatal pathway is involved in the presence of EPS such
as dystonia, akathisia, and concomitant movement disorders. Dopamine antagonism at
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receptor sites in these pathways produces motor dysfunction and other symptoms bearing
resemblance to Parkinson’s disease (Weiden, 2007). According to the DSM-IV-TR,
neuroleptic induced parkinsonism is “Parkinsonian tremor, muscular rigidity, or akinesia
developing within a few weeks of starting or raising the dose of a neuroleptic medication
(or after reducing a medication used to treat extrapyramidal symptoms)” (APA, 2000, p.
735). In order for EPS that affects motor functionality to arise, there needs to be an 80%
loss of DA content in the striatal area of the basal ganglia (Weiden, 2007). According to a
PET study, patients consistently report EPS when they are receiving neuroleptic drugs at
doses that involve an occupancy rate of over 80% at the D2 receptor (Farde, Mack,
Nyberg, & Halldin, 1997).
Due to the physical discomfort and social stigma associated with EPS, FGAs
producing these side effects often lead to a lower quality of life (Strejilevich et al., 2005),
poor treatment compliance (Buchanan, 1992), and increased mortality rates (Ballesteros,
Gonzalez-Pinto, & Bulbena, 2000). Patients with severe EPS also demonstrate impaired
perception and cognitive functioning (Krausz, Moritz, Naber, Lambert, & Andresen,
1999). Because treatments for EPS often demonstrate minimal effectiveness (Soares &
McGrath, 1999), EPS are often unavoidable and severe limitations of FGAs.
Other FGA side effects. Hyperprolactinemia is a common side effect of FGAs. By
occupying D2 receptors, FGAs cause a disinhibition of plasma prolactin levels by
blocking DA release (Ben-Jonathan & Hnasko, 2001). This inhibition of DA results in
elevated prolactin levels. Hyperprolactinemia can cause sexual side effects such as
irregular menstruation, lactation in women and men, and sexual dysfunction in men.
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Most FGAs, chlorpromazine and thioridazine in particular, have anticholinergic
actions (Crook, Tomaskovic-Crook, Coplov, & Dean, 2001). Administration of these
neuroleptic drugs increases the activity of presynaptic receptors in the central and
peripheral nervous symptoms that inhibit the release of acetylcholine (ACh), thus
depleting Ach levels (Lacroix, Hows, Shah, Hagan, & Heidbreder, 2003; Snyder,
Greenburg, & Yamamura, 1974). Depleted ACh levels lead to memory and learning
impairments (Kasper & Resinger, 2003). Other anticholinergic effects include dry mouth,
constipation, retention of urine, and blurred vision. The elderly are especially sensitive to
the anticholinergic effects of FGAs. High-potency FGAs are less anticholinergic and less
sedating than lower potency FGAs (Zhang & Bymaster, 1999). However, these highpotency agents are more likely to cause parkinsonism, akathesia, and dystonia
(Mukherjee, 1982; Snyder et al., 1974; Tarsy & Baldessarini, 2006). Because many
FGAs block DA transmission and have anticholinergic effects at muscarinic receptors
(Crook et al., 2001), these neuroleptics are more likely to produce tardive dyskinesia than
other neuroleptic drugs (Sayers, Burki, Ruch, & Asper, 1976).
Second Generation Antipsychotics
Second generation antipsychotics (SGAs) were introduced in the United States in
late 1980s. In 1989, clozapine (Clozaril) was the first SGAs antipsychotic to be approved
by the Food and Drug Administration (FDA). Other SGAs include: Risperdal
(risperidone) Zyprexa (olanzapine), Seroquel (quetiapine), Geodon (ziprasidone), and
Ability (aripiprazole). Second generation antipsychotics are characterized by a higher 5HT2/DA2 occupancy ratio than FGAs (Mamo et al., 2004). Studies have shown that
SGAs effectively reduce positive (Bouchard et al., 2000) and negative symptoms
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(Martyns-Yellowe, 1994), and the risk of relapse for schizophrenic patients without the
traditional side effects associated with FGAs (Haro & Salvador-Carulla, 2006). Because
SGAs demonstrate fewer and less severe EPS across all age groups (Correll, Leucht, &
Kane., 2004; Weiden, 2007), SGAs may contribute to a higher quality of life and greater
treatment compliance among schizophrenic patients than FGAs (Gerlach, 1999). Thus,
some have argued that SGAs have the capacity to diminish the incidence of acute
psychotic episodes that are responsible for frequent and long-lasting hospital stays. As a
result, SGAs have become the preferred pharmacotherapy for schizophrenia (Correll et
al., 2004).
Side effects o f SGAs. In addition to the potential benefits of SGAs, this class of
antipsychotics also has its own financial costs and medical risks. EPS is still a distressful
and problematic side effect of many SGAs, especially in elderly populations. Research
suggests that taking a high dose of some SGAs increases the risk of EPS (Correll et al.,
2004; Kane, 2001). Therefore, EPS is still common among schizophrenic patients taking
higher than recommended doses of SGAs such as clozapine, risperidone and olanzapine
(Correll et al., 2004; Weiden, 2007).
One o f the major limitations of SGAs is weight gain (Weiden, 2007). Weight gain
associated with SGAs increases the risk of developing metabolic syndrome (MS).
Research suggests that individuals whose weight increases by 5% are 200 times more
likely to develop MS (Everson et al., 1998). Therefore, patients taking SGAs are more
vulnerable to developing MS than individuals on FGAs.
The metabolic abnormalities associated with SGAs also increase the risk of
developing MS. Diagnosis for MS is established when there is a co-occurrence of at least
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three of the following conditions: elevated triglycerides, HDL cholesterol, blood
pressure, fasting glucose levels, and abdominal obesity (Expert Panel on Detection,
2001). Metabolic syndrome elevates the risk for cardiovascular disease, which is one of
the leading causes of morbidity and mortality among schizophrenic patients (Meyer,
2003). The insulin sensitivity and other metabolic abnormalities associated with MS often
predict diabetic complications. Metabolic syndrome can exacerbate pre-existing diabetes
mellitus or can significantly increase the risk of developing this condition (Newcomer et
al., 2002). Compared to the general population, individuals with schizophrenia are twice
as likely to be diagnosed with type 2 diabetes mellitus (Dixon et al., 2000).
The increased morbidity and mortality rates for many o f the conditions associated
with MS (e.g., obesity, diabetes mellitus, and cardiovascular disease) emphasize the
public health implications of SGAs (Jin, Meyer, & Jeste, 2004). Weight gain associated
with medication use often leads to treatment noncompliance (Baptista, 1999).
Schizophrenics with poor treatment compliance relapse more frequently than those who
comply with treatment. Therefore, weight gain associated with the use of SGAs may lead
to poor treatment prognosis. Not all SGAs have the same side effect profiles. However,
the potentially harmful side effects o f SGAs and high medical costs associated with
assessment and treatment of abnormalities in glucose and lipid metabolism (Nichols &
Brown, 2005) may counter-balance the potential benefits associated with these drugs.
Current Study
The treatment of schizophrenia is heavily reliant on financial, health, and social
care. Therefore, resources need to be directed at finding and implementing the most
effective and least costly treatment regimes. Many patients and clinicians discontinue
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antipsychotic treatments due to adverse side effects. Therefore, the goal of
pharmacological treatments for schizophrenia is to maximize treatment effectiveness
while limiting the number of side effects that lessen patients’ quality of life. Because
SGAs are associated with a reduced risk of EPS, researchers believed that the potential
clinical benefits of SGAs outweighed the costs associated with these drugs. However,
recent research has suggested that SGAs may not be superior to FGAs in terms of clinical
efficacy (Geddes, Freemantle, Harrison, & Bebbington, 2000). Furthermore, the potential
side effects (e.g., weight gain, metabolic abnormalities) associated with SGAs may
suggest that the medial risks and financial costs of these drugs counterbalance the
benefits of SGAs. Therefore, the aim of this study is to compare differences in weight,
lipid and glucose levels, and metabolic irregularities between individuals on first and
second generation antipsychotics while controlling for length of hospital stay and
psychosis. It is hypothesized that patients treated with SGAs will display more weight
gain and a higher prevalence of MS than individuals on FGAs. First generation
antipsychotics such as perphenazine and haloperidol appear to be just as effective in
treating schizophrenia as the following SGAs: quetiapine, risperidone, and ziprasidone
(Lieberman et al., 2005; Rosenheck et al., 2006). Therefore, it is hypothesized that FGAs
and SGAs will demonstrate similar clinical efficacy when collapsing across drug type.
Method
Research Design
Study participants were patients at Eastern State Hospital in Williamsburg,
Virginia. A research proposal was submitted and approved by the hospital's Institutional
Review Board (IRB). The research design was a retrospective, archival study of the
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medical files of patients. A list of patients admitted to Eastern State Hospital between
1990 and 1999 and being treated with an FGA was randomly generated from admission
records. An additional list of patients admitted to Eastern State Hospital between 2000
and 2006 and receiving treatment with an SGA was also created. From these lists, only
current or past patients receiving treatment with an FGA or SGA for at least a six-month
period were chosen for inclusion in the study. Individuals concurrently taking SGAs and
FGAs were excluded from participation in the study. Demographic, clinical, and medical
data were collected from patient files. Clinical and medical data were collected at two
points in time in order to evaluate change in disease course across time. A pre-treatment
assessment of the clinical variables was taken during the first month of admission into the
hospital. The most current or discharge assessment of clinical and medical variables was
recorded during December 2006. A standard de-identification process was used to protect
patient confidentiality and anonymity. Participants’ names, hospital record numbers, and
a unique ID number were maintained on a Master Subjects Form.
Table 1 lists gender, ethnicity, and education history. Ages at last assessment
ranged from 19 to 74 years (M = 44.20; Mdn = 44.00; SD = 12.09). Number of
admissions to a state psychiatric facility (including current admission) ranged from 1 to
24 (M = 6.62; Mdn = 5.00; SD = 5.59). Participants length of stay in the hospital ranged
from 0.21 to 13.99 years (M = 1.94; Mdn = 1.04; SD = 2.14). Table 2 lists Axis I and II
psychiatric diagnoses, and Axis IV psychosocial/environmental problems. Number of
Axis III medical conditions ranged from 0 to 8 (.M = 2.29; Mdn = 2.00; SD = 2.03).
Table 3 lists antipsychotic doses. Tables 4 and 5 list the prevalence of MS among patients
receiving FGAs and SGAs.
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Variables
A data collection form was developed to review each patient file. Demographic
variables collected included: age, gender, ethnicity, education history of the patient,
length of stay at hospital (LOS). Clinical variables were Axis I, II, III, IV, V (Global
Assessment of Functioning) diagnoses from the DSM-IV-TR (American Psychological
Association, 2000), Brief Psychiatric Rating Scale (BPRS) scores, and Mini Mental State
Exam (MMSE) scores. The BPRS (Overall & Gorham, 1962) is a scale designed to
measure the severity of psychiatric symptoms. The MMSE is used to assess cognitive
status in areas of orientation, memory, and attention (Folstein, Folstein, & McHugh,
1975). Medical variables included the following: medications and their administered
dosages, weight (lbs), BMI, blood pressure, and glucose and lipid levels.
Results
Statistical Measures
Frequency distributions were run on demographic variables (gender, age,
ethnicity, education, and diagnoses), clinical treatment efficacy variables (Global
Assessment of Functioning [GAF], BPRS total score, five BPRS scale scores, MMSE) at
each time interval, and physiological variables (diagnosis of MS, BMI (body mass
index), blood pressure, HDL, Triglycerides, and fasting glucose) at each time period.
Measures of central tendency, dispersion, and shape were run on ordinal and
interval/ratio scaled variables and continuously scaled variables.
An alpha level of 0.05 was used for all statistical analyses. Univariate and
multivariate repeated measures analyses o f variance were run to determine whether there
was a significant change in physiological measures and clinical scores from admission to
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last assessment. A separate analysis was run for diagnosis of MS, other physiological
measures, and clinical scales.
Analysis o f Covariance
A mixed model analysis of covariance (ANCOVA), with LOS and total number
of admissions as covariates, was conducted to determine whether there was a change in
mean scores on dependent measures across time period (admission, last assessment) and
treatment (FGA, SGA). Violation of sphericity was corrected for by means of the
Greenhouse-Geisser adjustment.
A mixed model ANCOVA was conducted on diagnosis of MS, with LOS and
total number of admissions as covariates. Results indicated a significant time x treatment
effect on diagnosis of MS F( 1, 77) = 4.66,/?= .034 (see Figure 1). Patients on SGAs had
a greater increase in diagnosis of MS from admission {M= .08, SD = .28) to last
assessment (M= .36, SD = .49) than patients on FGAs (admission, M = .18, SD = .39;
last assessment, M = .22, SD = .42),
For weight, there was a significant main effect of time, F(l, 91) = 9.51, p = .003.
Patients weighed less at admission ( M - 180.34, SD = 45.22) than at last assessment (M —
186.43, SD = 39.46). There was significant time x treatment effect on weight F (l, 91) =
7.22, p = .009. Patients on SGAs had a greater increase in weight from admission (M=
175.79, SD = 44.29) to last assessment (M= 188.69, SD = 37.91) than patients on FGAs
(admission, M = 183.80, SD = 46.02; last assessment, M = 184.71, SD —40.87).
A 2 x 2 mixed model multivariate analysis of covariance (MANCOVA), with
LOS and total number of admissions as covariates, was performed on six dependent
variables: BMI, systolic and diastolic blood pressure, HDL, Triglycerides, and fasting
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glucose. Independent variables were time period and treatment. With the use of Wilk’s
criterion, the combined DVs were not significantly affected by time or treatment. There
was a nearly significant time x treatment effect on the combined dependent variables F(6,
45) = 2.12, p = .069. Univariate tests within the MANCOVA reveal a significant time x
treatment effect on systolic blood pressure, F( 1, 50) = 7.40,/? = .009. Patients on SGAs
had a greater increase in systolic blood pressure from admission (A/= 121.07, SD =
11.54) to last assessment (.M= 127.48, SD = 13.00) than patients on FGAs (admission, M
= 131.85, SD = 16.95; last assessment, M = 122.93, SD = 13.29).
A mixed model ANCOVA on BPRS total scores, with LOS and total number of
admissions as covariates, indicated a main effect of time, F{ 1, 78) = 37.53,/? = .000.
Patients had higher BPRS total scores at admission (M= 40.98, SD = 10.81) than at last
assessment (M= 32.88, SD = 10.14). There was a non-significant main effect of
treatment and time x treatment effect. A 2 x 2 mixed model multivariate analysis of
variance (MANCOVA) was performed on the five BPRS subscales: withdrawal,
cognitive dysfunction, agitation, hostile suspiciousness, and psychotic distortion. The
combined dependent variables were significantly affected by time, F(5, 74) = 9.81,/? =
.000. Table 6 shows mean BPRS subscale scores between admission and last assessment.
No main effect for treatment or time x treatment effect on the combined dependent
variables was found.
Univariate mixed model ANCOVAs, with LOS and total number of admissions as
covariates, were conducted on Global Assessment of Functioning (GAF) and MMSE
scores. There was a significant main effect of time on GAF, F (1, 87) = 29.63,/? = .000.
Patients’ GAF was higher at last assessment (M = 47.55, SD = 14.55) than at admission
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(M= 31.62, SD =11.57). Treatment and time x treatment did not significantly affect
GAF. For MMSE scores, there was significant time x treatment effect, F (1, 30) = 6.47,/?
= .016 (see Figure 2). Patients treated with FGAs were more likely to improve on the
MMSE from admission (M= 21.00, SD = 7.83) to last assessment (M= 27.00, SD =
5.61) than those on SGAs (admission, M —24.89, SD = 4.78; last assessment, M = 25.79,
SD = 5.15). Time and treatment did not significantly affect MMSE scores.
Discussion
This study examined the prevalence of MS among schizophrenic and
schizoaffective patients receiving FGAs and SGAs. Results indicated that over the course
of one hospital admission, patients treated with SGAs were more likely to meet the
diagnostic criteria for MS than those on FGAs. Patients receiving SGAs also displayed
greater increases in weight and systolic blood pressure from first to last assessment than
those being treated with FGAs. In combination, these results support previous findings
that metabolic irregularities (Wu et al., 2006), weight gain (Casey, 2005), and
hypertension (Meltzer, Davidson, Alexander, Glassman, & Vieweg, 2002) are side
effects associated with SGA use.
Results from this study revealed that the interaction between time and treatment
significantly affected diagnosis of MS but not the combined physiological risk factors for
MS. These discrepancies reinforce that the diagnosis of MS is not merely an aggregate of
the following physiological variables: BMI, blood pressure, HDL, triglycerides, and
fasting glucose. Instead, MS is the co-occurrence of three of the following conditions:
obesity, elevated blood pressure, reduced HDL, elevated triglycerides, and elevated
fasting glucose. In order to meet the criteria for MS, patients did not have to evidence
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abnormalities in all of the aforementioned areas (Expert Panel on Detection, 2001).
Therefore, the results of the 2x2 mixed model ANCOVA are more appropriate for current
study than an analysis o f the combined physiological DVs. As a result, it can be
concluded that there is a higher prevalence of MS among patients treated with SGAs than
those receiving FGAs. This finding supports the main hypothesis of this study.
Results revealed no significant differences in Axis V or BPRS total and scale
scores from first to last assessment between treatment groups. This finding suggests that
SGAs and FGAs are similarly effective in reducing psychosis. The current study also
found that patients treated with FGAs demonstrated greater improvements in MMSE
scores over the course of one hospital admission than those on SGAs. This finding
suggests that FGAs benefit cognitive functioning more than SGAs. In combination, these
results indicate that SGAs are not superior to FGAs in terms of clinical efficacy.
Many researchers and clinicians have asserted the superior therapeutic efficacy of
SGAs over FGAs (Marder, 2003). However, when studies have collapsed antipsychotics
across drug type, as was done in the current study, results have indicated that SGAs have
little or no advantage over FGAs in terms of therapeutic efficacy. Geddes et al. (2000)
found that after controlling for higher than recommended FGA doses, tolerability and
clinical efficacy between FGAs and SGAs was similar. In addition, SGAs showed only a
slight advantage over FGAs in terms of EPS.
Methodological problems with many efficacy studies comparing FGAs to SGAs
have been identified (see Rosenheck, 2005 for review). Rosenheck (2005) found that the
quality of life and symptom reduction reported in many SGA efficacy studies may be
inflated and give unfair advantage to SGAs. After excluding FGA doses below the
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therapeutic range and FGA use without prophylactic anticholinergics, patients on lowpotency FGAs were not at greater risk of non-adherence, treatment discontinuation, or
developing EPS than SGAs. These findings indicate that FGAs and SGAs may have
comparable treatment effectiveness.
Given the lack of support found in the current study for the superiority of SGAs
on measures of therapeutic efficacy, the slightly lower risk of EPS associated with SGA
use appears to be abated by the greater risk of weight gain and MS among patients
receiving SGAs than those on FGAs. Metabolic syndrome is a financial burden. Given
the constellation of metabolic disorders necessary for establishing a diagnosis, it is not
surprising that MS is associated with an increased risk of obesity, diabetes, and
cardiovascular disease (Reaven, 2002). In conjunction with the much greater drug costs
of SGAs in comparison to FGAs, the annual health care costs of these conditions raise
concern about the high prevalence of MS among patients receiving SGAs.
In the general population, spending per person was 37% higher in 2001 for obese
persons than for those who were normal-weight (Thorpe, Florence, Howard, & Joski,
2004). Health risks associated with obesity include respiratory complications, certain
cancers, liver and gall bladder disease, and hypertension (Kopelman, 2007). Because
obesity both exacerbates and causes many health problems (Kopelman, 2007), obesity is
a societal and economic burden. The United States Department of Health and Human
Services (2001) estimated that overweight and obesity costs approximately $117 billion
annually.
Diabetes mellitus and cardiovascular diseases incur some of the highest health
care costs in the general population annually. The Center for Disease Control and
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Prevention (2003) estimated that the annual direct cost of diabetes is approximately $92
billion in the United States. Diabetes also carries a high risk o f mortality. In 2003,
diabetes was the sixth leading cause o f death (Hoyert, Kung, & Smith, 2005). The loss of
productivity associated with diabetes’ high mortality and morbidity rates contribute to the
$40 billion in indirect costs of this metabolic disorder annually.
Cardiovascular disease is the leading cause of death and disability worldwide
(Thom et al., 2006). Common types of cardiovascular disease include hypertension,
coronary artery disease, heart failure, and stroke. Approximately 34% o f all deaths in the
United States in 2004 were related to cardiovascular disease. Included in the estimates of
indirect costs of cardiovascular diseases is the loss of productivity associated with the
high rate of morbidity and mortality of these diseases. In the general population,
cardiovascular disease is the most costly disease in the United States incurring
approximately $400 billion annually (Thom et al., 2006).
In addition to causing economic strain, the personal costs associated with MS are
great. Metabolic syndrome adversely impacts one’s quality of life (Gardner,
Montgomery, & Parker, 2006). In addition, weight gain, which increases the risk of MS
(Everson et al., 1998), can lead to treatment non-compliance (Awad & Vorunganti,
2004). De Hert et al. (2006) found that patients with schizophrenia who experienced
recent weight gain had lower self-esteem and psychosocial adjustment than patients who
had not gained weight. Recent weight gain also leads to discontinuation of treatment.
When establishing the cost-effectiveness of antipsychotics, both the financial and
personal costs need to be evaluated. Second generation antipsychotics gained popularity
because they carry a lower risk of EPS than FGAs. Due to the debilitating nature of EPS,
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it was believed that SGAs contributed to a higher quality of life than FGAs. However,
given the large economic and personal costs o f MS and the higher prevalence of MS
found in this study among patients receiving SGAs than those on FGAs, the costeffectiveness of SGAs needs to be reexamined. The higher risk of MS and lack of support
for the superiority of SGAs in terms of clinical efficacy found in this study suggest that
the benefits of SGAs may not outweigh the side effects and financial cost of this class of
antipsychotics. Further research is needed to establish the direct and indirect costs of
SGAs as well as morbidity and mortality estimates of the side effects of SGAs (e.g.,
obesity, elevated blood pressure, and MS). In conjunction with the findings from this
study, these analyses could call into question the use of SGAs as a first-line treatment for
schizophrenia.
A key limitation of this research concerns the generalizability of the results. As
with all quasi-experimental designs, the findings of this study should be regarded with
caution. The small within group sample sizes of this study further limits the analyses of
clinical efficacy between specific FGAs and SGAs. Therefore, future research should
replicate this study using larger within group samples to determine the therapeutic
efficacy and effectiveness of specific SGAs. Furthermore, future efforts should also be
directed at determining how dose might affect the different side effect profiles of SGAs.
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Table 1

Demographic Variables

/

%

49
50

49.5
50.5

68
30
1

68.7
30.3
1.0

7
24
26
19
13
4

7.5
25.8
28.0
20.4
14.0
4.3

Gender
Male
Female
Ethnicity
African American
Caucasian
Hispanic
Education History
Less than High School
Some High School
Diploma or GED
Some College
College Degree
Graduate Degree
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Table 2
Primary Psychiatric Diagnoses and Psychosocial and Environmental Problems
Diagnostic Categories

/

%

39
60
28
18
7

39.4
60.6
28.3
18.2
7.1

Axis I and Axis II Diagnoses
Schizophrenia
Schizoaffective Disorders
Substance Disorders
Personality Disorders
Mild Mental Retardation

Axis IV Psychosocial and Environmental Problems
Primary Support Group
Social Environment
Educational
Occupational
Housing
Economic
Access to Health Care
Legal System/Crime
Other

24
5
0
9
23
2
37
30
1

24.2
5.1
0.0
9.1
23.2
2.0
37.4
30.3
1.0

Note. Percentage reflects percent of subjects with a diagnosis or problem in a given
category. Many subjects had more than one diagnosis and problem.
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Table 3
Antipsychotic Doses
Daily Dose (mgs)
Medication

/

%

Min

Max

M

Mdn

SD

FGAs (n = 56)
fluphenazine HC1

8

8.1

5.0

20.0

13.1

15.0

4.6

fluphenazine decanoate

13

13.1

0.2

5.4

2.7

3.6

1.7

haloperidol

19

19.2

5.0

45.0

19.3

20.0

10.2

haloperidol decanoate*

20

20.2

1.8

14.3

7.5

7.1

4.6

thioridazine

2

2.0

600.0

800.0

700.0

700.0

141.4

thiothixene

5

5.1

15.0

40.0

30.0

30.0

10.6

aripiprazole

2

2.0

30.0

30.0

30.0

30.0

0.0

clozapine

5

5.1

200.0

500.0

355.0

400.0

135.1

risperidone oral

12

12.1

4.0

8.0

5.7

6.0

1.4

risperidone consta

3

3.0

3.6

3.6

3.6

3.6

0.0

olanzapine

17

17.2

10.0

30.0

19.4

20.0

4.3

quetiapine

3

3.0

200.0

900.0

600.0

700.0

360.6

ziprasidone

4

4.0

160.0

160.0

160.0

160.0

0.0

SGAs (n = 43)

Patterns and Prevalence 23
Table 4
Metabolic Syndrome Among FGA Patients at Last Assessment
Metabolic Syndrome
Normal Range

High Risk

NCEP criteria

/

%

/

%

Fasting Glucose

>110 mg/dl

49

87.5

7

12.5

Hypertension

> 130/80

33

58.9

23

41.1

Triglycerides

>150 mg/dl

39

69.6

16

28.6

HDL Cholesterol

<40 mg/dl in women

26

46.4

12

21.4

<50 mg/dl in men
BMI

> 29.4 kg/m2

36

64.3

20

35.7

MS

any 3 of the above traits

38

67.9

12

21.4
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Table 5
Metabolic Syndrome Among SGA Patients at Last Assessment
Metabolic Syndrome
Normal Range

High Risk

NCEP criteria

/

%

/

%

Fasting Glucose

>110 mg/dl

34

79.1

8

18.6

Hypertension

> 130/80

22

51.2

21

48.8

Triglycerides

> 150 mg/dl

27

62.8

13

30.2

HDL Cholesterol

<40 mg/dl in women

20

46.5

18

41.9

<50 mg/dl in men
BMI

> 29.4 kg/m2

19

44.2

24

55.8

MS

any 3 of the above traits

25

58.1

14

32.6
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Table 6
Mean BPRS Subscales at Admission and Last Assessment
Last Assessment

Admission
BPRS Subscale
Withdrawal
Cognitive Dysfunction
Agitation
Hostile Suspiciousness
Psychotic Distortion

Mean

SD

Mean

SD

8.41

4.32

6.68

2.74

5.30

2.74

3.90

2.05

6.26

3.25

4.79

2.15

5.45

3.Q6

3.99

2.08

6.26

2.61

4.18

2.08
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Figure 1
Percentage of patients with MS
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Figure 2
Estimated marginal means for MMSE scores
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